AusBiotech is delighted to reveal a ‘sneak peek’ into the AusBiotech 2022 programme, which features global thought-leaders, and pressing and emerging topics to drive the Australian biotech sector forward.
Opening the largest annual biotech gathering for the Australian life science industry, Millis Orator keynote Professor Marvin Caruthers, Distinguished Professor at the University of Colorado, will address biotechnology industry transformation through ground-breaking DNA synthesis chemistry.
The Millis Oration is named in honour of Emeritus Professor Nancy Millis's contribution to the industry, and is held annually at the AusBiotech conference together with support from CSL. The Oration is a focal point of the annual industry gathering and is appropriately named in honour of this pioneer of Australia’s biotechnology industry.
Professor Caruthers has extensive industry experience as the co-founder of Amgen Pharmaceuticals and Applied Biosystems, and more recently, he is also a co-founder of Array BioPharma, miRagen Therapeutics and SynGenis Pty Ltd. The Oration will discuss how the supply of DNA/RNA is paramount to the biotechnology and life sciences sector for diagnostic, therapeutic, and research purposes.
Keynote Dr Lisa Haile, Partner, DLA Piper, will also present in person on the nexus of science and intellectual property and its impact on shaping the biotechnology sector globally. With a career spanning 30 years that has included working with nine Nobel prize winners, Dr Haile will talk about the global trends and implications of IP law on innovation, from the perspective of a world-leading expert in patent protection and strategy, as a professional who started as a microbiologist.
Dr Haile is an awarded expert in patent protection and IP transactional matters and has special technical experience in molecular biology, immunology, cell biology, regenerative medicine, gene editing, immuno-oncology, diagnostics, therapeutics, and drug delivery systems.
The three-day programme is hosted in Perth, WA from 26-28 October 2022, and is packed with pressing, emerging, and engaging topics, designed to connect the Australian biotech sector.
Join us to celebrate and connect with our thriving Australian and global biotechnology network throughout the biggest week in biotech; engage and exchange ideas, pitch, partner and learn.
AusBiotech 2022 is run by industry, for industry; and for more than three decades it has created a forum to reflect on the sector’s achievements and exchange ideas to further advance the industry.
The premier event brings together industry leaders, investors, researchers, clinicians and regulatory representatives from across the globe. All benefits from the conference flow back into the sector to continue facilitating the industry’s growth and global development, as AusBiotech is a not-for-profit entity.
Biotech’s biggest week also includes AusBioInvest 2022, Australia’s preeminent life science investment event, which will run concurrently on 27 October 2022. Australia’s biotechnology industry presents a compelling opportunity for investors and international partners, and it will encourage delegates to invest in health.
This independent event is designed to engage capital with innovation and offers the opportunity for companies to present their technology and story to a network of potential international partners and investors, including global pharma representatives. Companies interested in presenting are invited to express their interest; qualified and pre-approved investors are invited to register their free-of-charge attendance now.
AusBiotech’s premier biotech conferences, AusBiotech 2022 and AusBioInvest 2022, are proudly sponsored by the WA Government and Business Events Perth.
Come alive and take advantage of the AusBiotech 2022 early-bird registrations; register now.